ImmuCell Corporation (ICCC) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. ImmuCell Corporation is an animal health company focused on dairy and beef cattle, primarily through its First Defense product line (preventing scours in calves) and the development of Re-Tain (a treatment for subclinical mastitis). The company operates two reportable segments: Scours and Mastitis.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Product Sales | $6.44 million | $14.51 million | $5.47 million | $12.73 million |
| Gross Margin | $2.82 million (44%) | $6.17 million (43%) | $1.23 million (22%) | $3.53 million (28%) |
| Net Operating Income | $0.57 million | $1.69 million | ($1.39 million) | ($1.69 million) |
| Net Income (Loss) | $0.50 million | $1.95 million | ($1.53 million) | ($1.97 million) |
| Cash and Equivalents | $6.00 million | $6.00 million | $3.76 million (Dec 31, 2024) | $1.32 million (Jun 30, 2024) |
| Total Debt (Gross) | $9.80 million | $9.80 million | $10.54 million (Dec 31, 2024) | $10.54 million (Dec 31, 2024) |
| Operating Cash Flow | N/A | $3.18 million | N/A | $1.00 million |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability, reporting net income of $1.95 million for the six months ended June 30, 2025, compared to a net loss of $1.97 million in the same period in 2024. This $3.9 million swing was driven by a $2.6 million increase in gross margin and a $0.73 million reduction in operating expenses.
- Gross Margin Expansion: Gross margin percentage improved significantly to 43% (YTD 2025) from 28% (YTD 2024). This improvement is attributed to the resolution of production backlogs, price increases implemented in late 2023 and early 2025, and improved production yields.
- Revenue Growth: Product sales increased 14% year-over-year for the six-month period. International sales grew 64% year-over-year, now representing 17% of total sales.
- Backlog Reduction: The order backlog, which had reached approximately $9.1 million in early 2024, was reduced to less than $100,000 as of June 30, 2025.
- Contamination Events: The company experienced a new production contamination event in Q2 2025, resulting in approximately $208,000 in scrapped inventory costs. This impacted the gross margin, which would have been 47% without the scrap costs.
Guidance, Outlook, and Risks
- Re-Tain Development: The company is awaiting FDA approval for Re-Tain. The critical path constraint is currently the resolution of inspectional observations at the contract manufacturer's facility. The company has implemented an "aggressive idle" strategy for product development expenses to reduce cash burn while maintaining the ability to resume production quickly.
- Debt Refinancing (Subsequent Event): In August 2025, the company refinanced approximately $2.3 million of existing debt (Loans #6 and #7) into a new loan with a lower interest rate (6.5%) and a 5-year term, removing balloon payments due in 2026.
- Liquidity: Management projects that existing cash and anticipated gross margins will be sufficient to fund operations for at least the next 12 months. The company continues to utilize an At-The-Market (ATM) offering program for capital flexibility.
- Risks:
- Customer Concentration: Two distributors accounted for 75% of sales and 79% of accounts receivable as of June 30, 2025.
- Production Contamination: Ongoing risk of biological contamination events which can lead to inventory scrap and production slowdowns.
- Regulatory Approval: Delays in FDA approval for Re-Tain or failure to secure a new contract manufacturer for Drug Product (DP) filling could impact future revenue streams.
- Debt Covenants: The company must meet a minimum Debt Service Coverage (DSC) ratio of 1.35 for the year ending December 31, 2025. The trailing twelve-month DSC ratio as of June 30, 2025, was 2.64.
Investor Verification Checklist
- Verify Debt Covenant Compliance: Confirm the company's ability to maintain the 1.35 DSC ratio for the full year 2025, given the recent refinancing and ongoing operational costs.
- Monitor Re-Tain FDA Status: Track the resolution of inspectional observations at the contract manufacturer's facility, which is the current bottleneck for FDA approval.
- Assess Contamination Frequency: Review future filings for recurrence of production contamination events, which significantly impact gross margins and cash flow.
- Customer Concentration Risk: Evaluate the financial health and relationship stability of the two primary distributors representing 75% of sales.
- Inventory Levels: Monitor Work-in-Process inventory levels, which have been high due to raw material accumulation, to ensure efficient conversion to finished goods and cash.